Fate Therapeutics Inc 2024年度报告

2024 Annual Report Dedicated to bringing a first-in-class pipeline of iPSC-derived cellular immunotherapies to patients Tcells |NKcells |CD34+cells inducedPluripotentStemCell Platforma renewable source for off-the-shelf engineered cell products FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☐or No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐or No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒or No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒ The aggregate market value of the common stock held by non-affiliates of the registrant was approximately $369,000,000 as of June 30, 2024 based upon the closing saleprice on The Nasdaq Global Market reported for such date. Shares of common stock held by each executive officer and director and certain holders of more than 10% of theoutstanding shares of the registrant’s common stock have been excluded in that such persons may be deemed to be affiliates. Shares of common stock held by other persons,including certain other holders of more than 10% of the outstanding shares of common stock, have not been excluded in that such persons are not deemed to be affiliates. Thisdetermination of affiliate status is not necessarily a conclusive determination for other purposes. The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of February 25, 2025 was 114,597,425. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, on or before the date 120 days after theconclusion of the registrant’s fiscal year ended December 31, 2024 pursuant to Regulation 14A, in connection with the registrant’s 2025 Annual Meeting of Stockholders areincorporated by reference into Part III of this annual report on Form 10-K. FATE THERAPEUTICS, INC.Annual Report on Form 10-KFor the Fiscal Year Ended December 31, 2024 TABLE OF CONTENTS PageRISK FACTOR SUMMARY........................................................................................................................................................1FORWARD-LOOKING STATEMENTS.....................................................................................................................................3PART IItem 1.Business......................................................................................................................................................................5Item 1A.Risk Factors................................................................................................................................................................38Item 1B.Unresolved Staff Comments ......................................................................................................................................84Item 1C.Cybersecurity ............................................................................................................................